Select all the resources you are interested in downloading.
ICH (International Council for Harmonisation) Q7 is the internationally harmonized Good Manufacturing Practice (GMP) guideline. It defines the requirements for producing active pharmaceutical ingredients (APIs) used in human and veterinary drug products. ICH Q7 covers the full API lifecycle, from raw material sourcing and intermediate processing to purification, packaging, and storage. This guideline establishes the standards manufacturers must follow to ensure products are consistently safe, pure, and of high quality. Its focus is the unique risks associated with chemical synthesis, fermentation, biological processing, and multi-step manufacturing operations.
The guideline outlines expectations for:
As APIs are manufactured and shipped across global supply chains, ICH Q7 serves as a common standard used by regulators such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the UK’s Medicinces and Healthcare products Regulatory Agency (MHRA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and World Health Organization (WHO) inspectors. It harmonizes expectations for compliance through a unified framework.
ICH Q7 is the foundation of global API quality standards. First published in 2000, it is the only internationally harmonized GMP document exclusively designed for active pharmaceutical ingredients.
Here’s how the guideline operates within the broader pharmaceutical quality ecosystem:
ICH Q7 applies to all stages of API manufacturing for clinical and commercial use. This includes chemical synthesis, fermentation, purification, packaging, and labeling of bulk APIs.
It carefully defines the point at which full GMP requirements begin, typically the introduction of the regulatory starting material.
The guideline serves as the technical foundation for EU GMP Part II. It is directly referenced in FDA inspections of API facilities.
It complements the U.S. 21 CFR Parts 210/211 for finished pharmaceuticals and Part 820 for medical devices.
It integrates seamlessly with the other ICH quality guidelines:
Q8 (Pharmaceutical Development) for science-based process understanding.
Q9 (Quality Risk Management) for systematic risk identification and control.
Q10 (Pharmaceutical Quality System) for lifecycle management and continual improvement.
ICH Q7 eliminates conflicting national requirements that previously caused duplicate audits and delayed approvals.
It functions as the primary evaluation criterion during pre-approval inspections (PAI) and marketing-authorization reviews.
It is now the de facto qualification standard for contract manufacturing organizations (CMOs) and suppliers in Asia, India, and emerging markets.
Overall, ICH Q7 drives consistent, risk-based API manufacturing practices worldwide. It ensures traceable, reproducible quality from the earliest chemical steps to the bulk active ingredients delivered to drug-product facilities. Its purpose is to safeguard patient safety across international supply chains.
ICH Q7 sets the global GMP standard for active pharmaceutical ingredients. It covers everything from facilities to final release. Below, you’ll find a breakdown of its core requirements:
In ICH Q7, manufacturers will find both operational and documentation requirements to ensure APIs are manufactured under controlled, reproducible, and auditable conditions. Under this guideline, organizations must maintain written procedures for critical activities (e.g., material receipt, in-process testing, and storage). From there, manufacturers must support these procedures with evidence, such as training records and real-time data capture.
The guideline provides expectations for facility and equipment design. Specifically, areas must be designed to:
Prevent cross-contamination.
Enable proper flow of personnel and materials.
Support cleaning verification.
Equipment must be qualified, calibrated, and maintained according to schedule. Records must be available for inspection by regulators.
Under ICH Q7, organizations are required to validate critical manufacturing steps, cleaning procedures, analytical methods, and computerized systems. Validation protocols must include predefined acceptance criteria and scientifically justified sampling strategies. Ongoing process verification is also required to demonstrate continued consistency across APIs.
Key documentation practices include:
Batch records.
Deviation reports.
Change controls.
Supplier qualifications.
Laboratory data.
Also consider data integrity controls so you can demonstrate that information is complete, accurate, and traceable.
Under ICH Q7, manufacturers must:
Identity, strength, purity, and quality testing required for intermediates (if applicable) and final APIs.
Meet stability standards when APIs are expected to be stored for extended periods.
Perform the final release by the quality unit based on documented evidence of compliance.
Any deviations, out of specification (OOS) results, and critical failures must be investigated, corrected, and documented. Compliance should be treated like a living system. Monitor, inspect, adapt, and repeat across the entire lifecycle of the product.
For API manufacturers, ICH Q7 is the operational backbone for producing safe, consistent ingredients used in finished pharmaceuticals. API production often involves complex chemical transformations or biological processes. As such, this guideline provides a structured approach for controlling variability, maintaining equipment reliability, and ensuring that intermediates meet defined specifications. Alignment with ICH Q7 supports the following across global sites:
Rigorous material traceability.
Contamination control.
Batch-to-batch reproducibility.
ICH Q7 is especially relevant for facilities that manufacture high-potency APIs, fermentation-based ingredients, or multi-step synthetic compounds. Manufacturers are required to document each production stage, validate critical process parameters, and maintain complete data integrity. These requirements are designed to prevent compromised batches from entering downstream supply chains. Manufacturers can streamline documentation workflows and reduce manual errors by integrating digital QMS solutions like MasterControl.
CMOs play an essential role in global pharmaceutical supply chains. ICH Q7 is the framework they need to deliver high-quality APIs to multiple clients and markets. As CMOs often manage diverse product portfolios and variable production schedules, this framework ensures consistent quality oversight (regardless of client requirements or manufacturing complexity). It defines how facilities must:
Control risk.
Document production data.
Qualify suppliers.
Manage client communications.
ICH Q7 also supports transparent, audit-ready operations, which is key for sponsors evaluating potential outsourcing partners. CMOs must demonstrate robust change control, validated processes, environmental monitoring, and data integrity practices. They must also conduct deviation investigations and provide complete batch documentation to clients and regulators. MasterControl’s digital QMS platform is designed to enhance CMO performance. It centralizes records, enables real-time document sharing, automates corrective action/preventive action (CAPA) processes, and standardizes operational workflows across multiple sites and customers.
When designing early pharmaceutical manufacturing processes that will eventually scale to commercial production, ICH Q7 can inform development-stage activities. Specifically, development teams use ICH Q7 principles to:
Establish impurity profiles.
Define critical process parameters.
Create preliminary batch documentation that aligns with future GMP expectations.
Overall, it ensures smooth transitions as products move from laboratory synthesis to pilot-scale and full-scale API production.
During the process development phase, ICH Q7 supports several key areas:
Risk assessments.
Method validation strategies.
Material traceability practices.
Documentation standards.
These elements carry forward into later lifecycle stages. It also brings together R&D, quality, and manufacturing teams. ICH Q7 establishes shared expectations around cleanliness controls, equipment qualification, and data integrity. When teams follow ICH Q7 principles from the beginning of development, they avoid a lot of headaches later. This approach cuts down on costly rework, unexpected regulatory issues, and problems when scaling up production. Development teams can lean on MasterControl’s QMS to keep version control tight, track each and every change to protocols, and retain full historical records as processes change and grow.
To demonstrate ICH Q7 compliance, organizations need controlled, traceable, and contemporaneous documentation for all GMP activities. That includes significant steps such as batch records, equipment logs, cleaning verification, training records, and deviation investigations. Ensure your records follow ALCOA+ data integrity principles. They should be accurate, legible, original, and auditable. You will want to retain records long enough to cover the product’s lifecycle plus one year. Electronic systems should include audit trails, security controls, and role-based access to support compliance.
Validation requirements for manufacturing processes under ICH Q7 include validating critical process steps, cleaning procedures, analytical methods, and computerized systems. This is done by following documented protocols that include predefined acceptance criteria and scientifically justified sampling strategies. Organizations must run multiple batches to serve as evidence of reproducibility across multiple batches. From there, plan for ongoing verification and periodic review to ensure processes continue to perform consistently throughout the product lifecycle.
The key components of an ICH Q7-compliant QMS are:
Procedure documentation capabilities.
Change control.
Deviation management.
Audit management capabilities.
Training program management.
Supplier qualification.
Systems for maintaining data integrity.
It must also support equipment qualification, calibration, sample handling controls, and batch record management. A robust QMS will drive the consistent application of GMP principles and provide the oversight needed to detect, investigate, and mitigate quality risks.
ICH Q7 clearly defines the operational GMP requirements for API manufacturing. On the other hand, ICH Q9 provides the risk management framework used to prioritize and control process risks. ICH Q10 extends these expectations into a holistic pharmaceutical quality system that promotes continuous improvement. Together, these three guidelines create an integrated model that links daily manufacturing practices with strategic quality oversight and lifecycle management.